Durability of the Mitroflow pericardial valve at ten years.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 7646177.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
From 1983 to 1992, 366 patients received 407 Mitroflow pericardial valves. Mean age was 62 +/- 14 years. Average follow-up was 72 +/- 28 months. Total follow-up was 1,791 patient-years. Overall survival in all patients was 77.2% +/- 2.2% at 5 years and 56.2% +/- 6.4% at 10 years. Freedom from structural valve deterioration was 95% +/- 1.2% and 36.7% +/- 8.1% at 5 and 10 years for all valves, 96.9% +/- 1.3% and 39.2% +/- 9.8% for aortic valve replacement, and 91.7% +/- 3.2% and 36.4% +/- 10% for mitral valve replacement (p = not significant). The freedom from structural valve deterioration in patients older than 70 years of age was 100% and 93.9% +/- 5.8% at 5 and 10 years, respectively. At 10 years, linearized rate of thromboembolism was 0.73% +/- 0.2% per patient-year and freedom from valve-related mortality for all valves was 88.8% +/- 2.8%. The best indication for the implantation of a Mitroflow valve is mitral or aortic disease in patients more than 70 years of age.
Medical subject headings
- Bioprosthesis
- Heart Valve Prosthesis